Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus
Ecological changes, population movements and increasing urbanization promote the expansion of hantaviruses, placing humans at high risk of virus transmission and consequent diseases. The currently limited therapeutic options make the development of antiviral strategies an urgent need. Ribavirin is the only antiviral used currently to treat hemorrhagic fever with renal syndrome (HFRS) caused by Hantaan virus (HTNV), even though severe side effects are associated with this drug. We therefore investigated the antiviral activity of favipiravir, a new antiviral agent against RNA viruses. Both ribavirin and favipiravir demonstrated similar potent antiviral activity on HTNV infection. When combined, the efficacy of ribavirin is enhanced through the addition of low dose favipiravir, highlighting the possibility to provide better treatment than is currently available.
Top-30
Journals
|
1
2
3
|
|
|
Viruses
3 publications, 12%
|
|
|
International Journal of Molecular Sciences
1 publication, 4%
|
|
|
Infectious Diseases and Therapy
1 publication, 4%
|
|
|
EBioMedicine
1 publication, 4%
|
|
|
Frontiers in Pediatrics
1 publication, 4%
|
|
|
ACS Nano
1 publication, 4%
|
|
|
Antimicrobial Agents and Chemotherapy
1 publication, 4%
|
|
|
Infection and Drug Resistance
1 publication, 4%
|
|
|
Journal of Biomolecular Structure and Dynamics
1 publication, 4%
|
|
|
Antibiotiki i Khimioterapiya
1 publication, 4%
|
|
|
Frontiers in Veterinary Science
1 publication, 4%
|
|
|
Biosciences Biotechnology Research Asia
1 publication, 4%
|
|
|
Virus Research
1 publication, 4%
|
|
|
Pharmaceutics
1 publication, 4%
|
|
|
Transplant Infectious Disease
1 publication, 4%
|
|
|
Russian Chemical Reviews
1 publication, 4%
|
|
|
Antiviral Research
1 publication, 4%
|
|
|
Molecular Diversity
1 publication, 4%
|
|
|
Frontiers in Immunology
1 publication, 4%
|
|
|
COVID
1 publication, 4%
|
|
|
PLoS Pathogens
1 publication, 4%
|
|
|
Transboundary and Emerging Diseases
1 publication, 4%
|
|
|
Biochemical and Biophysical Research Communications
1 publication, 4%
|
|
|
1
2
3
|
Publishers
|
1
2
3
4
5
6
|
|
|
MDPI
6 publications, 24%
|
|
|
Elsevier
4 publications, 16%
|
|
|
Frontiers Media S.A.
3 publications, 12%
|
|
|
Springer Nature
2 publications, 8%
|
|
|
Taylor & Francis
2 publications, 8%
|
|
|
Wiley
2 publications, 8%
|
|
|
American Chemical Society (ACS)
1 publication, 4%
|
|
|
American Society for Microbiology
1 publication, 4%
|
|
|
Publishing House OKI
1 publication, 4%
|
|
|
Oriental Scientific Publishing Company
1 publication, 4%
|
|
|
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii
1 publication, 4%
|
|
|
Public Library of Science (PLoS)
1 publication, 4%
|
|
|
1
2
3
4
5
6
|
- We do not take into account publications without a DOI.
- Statistics recalculated weekly.